Aarkstore -Glycoprotein Inhibitors -Pipeline Insights, 2014 - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore -Glycoprotein Inhibitors -Pipeline Insights, 2014 PowerPoint presentation | free to download - id: 6c10c7-ZTBiZ



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore -Glycoprotein Inhibitors -Pipeline Insights, 2014

Description:

DelveInsights,Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors. – PowerPoint PPT presentation

Number of Views:7
Slides: 15
Provided by: addyparker2350

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore -Glycoprotein Inhibitors -Pipeline Insights, 2014


1
Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/73733/glycoprotein-iib-iiia-gpiibiiia-inhibitors
    -pipeline-insights-2014

2
Summary
  • DelveInsights,Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA). A
    key objective of the report is to establish the
    understanding for all the pipeline drugs that
    fall under Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors. This report provides information on
    the therapeutic development based on the
    Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
    dealing with mechanism of action, comparative
    analysis at various stages covering Filed, Phase
    III, Phase II, Phase I, IND filed, Preclinical,
    Discovery and unknown stages, therapeutics
    assessment by monotherapy and combination
    products and molecule type drug information. The
    report also covers the companies information
    involved in the therapeutic development of the
    products. It also has highlighted the
    discontinued and dormant products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts. Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases. Please note this report
    requires certain updates. We have all the
    information available but require 3 business days
    to complete the process and ensure it is as
    up-to-date as possible. Certain sections in the
    report may be removed or altered based on the
    availability and relevance of data for the
    indicated mechanism of action. 

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Glycoprotein IIb-IIIa
    (GPIIb/IIIa) Inhibitors The report provides
    pipeline products under drug profile section
    which includes product description, MOA,
    licensors collaborators, development partner
    and chemical information Coverage of the
    Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
    pipeline on the basis of target, MOA, route of
    administration, technology involved and molecule
    type The report reviews key players involved in
    the therapeutics development for Glycoprotein
    IIb-IIIa (GPIIb/IIIa) Inhibitors and also provide
    company profiling The report also gives the
    information of dormant and discontinued pipeline
    projects  Pipeline products coverage based on
    various stages of development ranging from
    preregistration till discovery and undisclosed
    stages  Provides pipeline assessment by
    monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buy Complete MOA intelligence and
    complete understanding over therapeutics
    development for Glycoprotein IIb-IIIa
    (GPIIb/IIIa) Inhibitors
  • Identify the relationship between the drugs and
    use it for target finding, drug repurposing, and
    precision medicine.
  • Devise corrective measures for pipeline projects
    by understanding Glycoprotein IIb-IIIa
    (GPIIb/IIIa) Inhibitors pipeline depth and focus
    of Indication therapeutics
  • Developing strategic initiatives to support your
    drug development activities.
  • Optimize your portfolio and keep you in touch
    with the rapidly changing pharmaceutical markets,
    and make the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope
  • Provides strategically significant competitor
    information, analysis, and insights to formulate
    effective RD development strategies
  • Modify the therapeutic portfolio by identifying
    discontinued projects and understanding the
    factors that drove them from pipeline
  • Gaining a Full Picture of the Competitive
    Landscape for Evidence based Decision

7
Table of Content
  • Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
    Overview Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Disease Associated Glycoprotein
    IIb-IIIa (GPIIb/IIIa) Inhibitors Pipeline
    Therapeutics Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Therapeutics under Development by
    Companies  Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Late Stage Products (Filed and Phase
    III) Comparative Analysis  Glycoprotein IIb-IIIa
    (GPIIb/IIIa) Inhibitors Mid Clinical Stage
    Products (Phase II) Comparative
    Analysis  Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Early Clinical Stage Products (Phase I
    and IND Filed) Comparative Analysis  Glycoprotein
    IIb-IIIa (GPIIb/IIIa) Inhibitors Discovery and
    Pre-Clinical Stage Products  Comparative
    Analysis  Drug Candidate Profiles

8
Table of Content
  • Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
    Therapeutics Assessment  Assessment by
    Monotherapy Products  Assessment by Combination
    Products  Assessment by Route of
    Administration  Assessment by Molecule
    Type  Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Discontinued Products  Glycoprotein
    IIb-IIIa (GPIIb/IIIa) Inhibitors Dormant
    Products Companies Involved in Therapeutics
    Development for Glycoprotein IIb-IIIa
    (GPIIb/IIIa) Inhibitors  Appendix  Methodology  Co
    ntact Us  Disclaimer

9
List of Tables
  • Number of Products under Development for
    Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors by
    Therapy Area, 2014 Number of Products under
    Development for Glycoprotein IIb-IIIa
    (GPIIb/IIIa) Inhibitors, 2014 Number of Products
    under Development by Companies  Comparative
    Analysis by Late Clinical Stage Products (Filed
    and Phase III), 2014 Comparative Analysis Mid
    Clinical Stage Products (Phase II),
    2014 Comparative Analysis Early Clinical Stage
    Products (Phase I and IND Filed),
    2014 Comparative Analysis Discovery and
    Pre-Clinical Stage Products, 2014 Drug Candidates
    Profiles Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Assessment by Monotherapy Products 

10
List of Tables
  • Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
    Assessment by Combination Products  Glycoprotein
    IIb-IIIa (GPIIb/IIIa) Inhibitors Assessment by
    Route of Administration  Glycoprotein IIb-IIIa
    (GPIIb/IIIa) Inhibitors Assessment by Stage and
    Route of Administration  Glycoprotein IIb-IIIa
    (GPIIb/IIIa) Inhibitors Assessment by Molecule
    Type  Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Assessment by Stage and Molecule
    Type  Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Therapeutics Discontinued
    Products  Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Therapeutics Dormant Products Products
    under Development by Companies, 2014

11
List of Figures
  • Number of Products under Development for
    Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors by
    Therapy Area, 2014 Number of Products under
    Development for Glycoprotein IIb-IIIa
    (GPIIb/IIIa) Inhibitors, 2014 Late Clinical Stage
    Products (Filed and Phase III), 2014 Mid Clinical
    Stage Products (Phase II), 2014 Early Clinical
    Stage Products (Phase I and IND Filed),
    2014 Discovery and Pre-Clinical Stage Products,
    2014 Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Assessment by Monotherapy
    Products  Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Assessment by Combination
    Products  Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Assessment by Route of
    Administration  Glycoprotein IIb-IIIa
    (GPIIb/IIIa) Inhibitors Assessment by Stage and
    Route of Administration  Glycoprotein IIb-IIIa
    (GPIIb/IIIa) Inhibitors Assessment by Molecule
    Type  Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors Assessment by Stage and Molecule Type

12
Related Reports
  • 2015 Worldwide Medical Laboratories
    Industry-Industry Market Report
  • 2015 Worldwide Pharmaceutical Preparation Mfg.
    Industry-Industry Market Report
  • OncoPlex Diagnostics - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • MetaStat, Inc. - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Advanced Cell Diagnostics, Inc. - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review
  • Jazz Pharmaceuticals plc (JAZZ) - Financial and
    Strategic SWOT Analysis Review
  • Pharmstandard (PHST) - Financial and Strategic
    SWOT Analysis Review
  • GLG Life Tech Corporation (GLG) - Financial and
    Strategic SWOT Analysis Review

13
  • Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
    -Pipeline Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights,Glycoprotein IIb-IIIa (GPIIb/IIIa)
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA).

  • Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor, B-Wing,
Mahaavir Icon,  Plot No.- 89 90,
Sector-15, CBD-Belapur, Navi Mumbai
400614,  Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com